StockNews.com assumed coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research report released on Monday. The firm issued a sell rating on the biotechnology company’s stock.
Separately, Roth Mkm reduced their target price on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday, September 23rd.
Get Our Latest Research Report on APVO
Aptevo Therapeutics Trading Up 3.5 %
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.26. Equities research analysts anticipate that Aptevo Therapeutics will post -2.97 EPS for the current fiscal year.
Institutional Investors Weigh In On Aptevo Therapeutics
An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics at the end of the most recent quarter. 8.06% of the stock is owned by institutional investors.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Further Reading
- Five stocks we like better than Aptevo Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Most Volatile Stocks, What Investors Need to Know
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
